Identification of allosteric binding sites for PI3Kα oncogenic mutant specific inhibitor design

Michelle S. Miller, Sweta Maheshwari, Fiona M. McRobb, Kenneth W. Kinzler, L. Mario Amzel, Bert Vogelstein, Sandra B. Gabelli

Research output: Research - peer-reviewArticle

Abstract

PIK3CA, the gene that encodes the catalytic subunit of phosphatidylinositol 3-kinase α (PI3Kα), is frequently mutated in breast and other types of cancer. A specific inhibitor that targets the mutant forms of PI3Kα could maximize treatment efficiency while minimizing side-effects. Herein we describe the identification of novel binding pockets that may provide an opportunity for the design of mutant selective inhibitors. Using a fragment-based approach, we screened a library of 352 fragments (MW < 300 Da) for binding to PI3Kα by X-ray crystallography. Five novel binding pockets were identified, each providing potential opportunities for inhibitor design. Of particular interest was a binding pocket near Glu542, which is located in one of the two most frequently mutated domains.

LanguageEnglish (US)
Pages1481-1486
Number of pages6
JournalBioorganic and Medicinal Chemistry
Volume25
Issue number4
DOIs
StatePublished - Feb 15 2017

Fingerprint

Phosphatidylinositol 3-Kinase
Allosteric Site
Binding Sites
X Ray Crystallography
Libraries
Catalytic Domain
Breast Neoplasms
Genes
X ray crystallography

Keywords

  • Fragment-based drug discovery
  • PI3K
  • PIK3CA
  • PIP
  • PIP

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Medicine
  • Molecular Biology
  • Pharmaceutical Science
  • Drug Discovery
  • Clinical Biochemistry
  • Organic Chemistry

Cite this

Identification of allosteric binding sites for PI3Kα oncogenic mutant specific inhibitor design. / Miller, Michelle S.; Maheshwari, Sweta; McRobb, Fiona M.; Kinzler, Kenneth W.; Amzel, L. Mario; Vogelstein, Bert; Gabelli, Sandra B.

In: Bioorganic and Medicinal Chemistry, Vol. 25, No. 4, 15.02.2017, p. 1481-1486.

Research output: Research - peer-reviewArticle

@article{7a240ca3777246ecaf1906b06f421b71,
title = "Identification of allosteric binding sites for PI3Kα oncogenic mutant specific inhibitor design",
abstract = "PIK3CA, the gene that encodes the catalytic subunit of phosphatidylinositol 3-kinase α (PI3Kα), is frequently mutated in breast and other types of cancer. A specific inhibitor that targets the mutant forms of PI3Kα could maximize treatment efficiency while minimizing side-effects. Herein we describe the identification of novel binding pockets that may provide an opportunity for the design of mutant selective inhibitors. Using a fragment-based approach, we screened a library of 352 fragments (MW < 300 Da) for binding to PI3Kα by X-ray crystallography. Five novel binding pockets were identified, each providing potential opportunities for inhibitor design. Of particular interest was a binding pocket near Glu542, which is located in one of the two most frequently mutated domains.",
keywords = "Fragment-based drug discovery, PI3K, PIK3CA, PIP, PIP",
author = "Miller, {Michelle S.} and Sweta Maheshwari and McRobb, {Fiona M.} and Kinzler, {Kenneth W.} and Amzel, {L. Mario} and Bert Vogelstein and Gabelli, {Sandra B.}",
year = "2017",
month = "2",
doi = "10.1016/j.bmc.2017.01.012",
volume = "25",
pages = "1481--1486",
journal = "Bioorganic and Medicinal Chemistry",
issn = "0968-0896",
publisher = "Elsevier Limited",
number = "4",

}

TY - JOUR

T1 - Identification of allosteric binding sites for PI3Kα oncogenic mutant specific inhibitor design

AU - Miller,Michelle S.

AU - Maheshwari,Sweta

AU - McRobb,Fiona M.

AU - Kinzler,Kenneth W.

AU - Amzel,L. Mario

AU - Vogelstein,Bert

AU - Gabelli,Sandra B.

PY - 2017/2/15

Y1 - 2017/2/15

N2 - PIK3CA, the gene that encodes the catalytic subunit of phosphatidylinositol 3-kinase α (PI3Kα), is frequently mutated in breast and other types of cancer. A specific inhibitor that targets the mutant forms of PI3Kα could maximize treatment efficiency while minimizing side-effects. Herein we describe the identification of novel binding pockets that may provide an opportunity for the design of mutant selective inhibitors. Using a fragment-based approach, we screened a library of 352 fragments (MW < 300 Da) for binding to PI3Kα by X-ray crystallography. Five novel binding pockets were identified, each providing potential opportunities for inhibitor design. Of particular interest was a binding pocket near Glu542, which is located in one of the two most frequently mutated domains.

AB - PIK3CA, the gene that encodes the catalytic subunit of phosphatidylinositol 3-kinase α (PI3Kα), is frequently mutated in breast and other types of cancer. A specific inhibitor that targets the mutant forms of PI3Kα could maximize treatment efficiency while minimizing side-effects. Herein we describe the identification of novel binding pockets that may provide an opportunity for the design of mutant selective inhibitors. Using a fragment-based approach, we screened a library of 352 fragments (MW < 300 Da) for binding to PI3Kα by X-ray crystallography. Five novel binding pockets were identified, each providing potential opportunities for inhibitor design. Of particular interest was a binding pocket near Glu542, which is located in one of the two most frequently mutated domains.

KW - Fragment-based drug discovery

KW - PI3K

KW - PIK3CA

KW - PIP

KW - PIP

UR - http://www.scopus.com/inward/record.url?scp=85010443302&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85010443302&partnerID=8YFLogxK

U2 - 10.1016/j.bmc.2017.01.012

DO - 10.1016/j.bmc.2017.01.012

M3 - Article

VL - 25

SP - 1481

EP - 1486

JO - Bioorganic and Medicinal Chemistry

T2 - Bioorganic and Medicinal Chemistry

JF - Bioorganic and Medicinal Chemistry

SN - 0968-0896

IS - 4

ER -